Literature DB >> 9511180

A rare CYP19 (aromatase) variant may increase the risk of breast cancer.

V N Kristensen1, T I Andersen, A Lindblom, B Erikstein, P Magnus, A L Børresen-Dale.   

Abstract

The aromatase P450 (coded by the CYP19 gene) is responsible for the rate limiting step in the metabolism of C19 steroids to estrogens and is expressed in most breast carcinomas. A polymorphic tetranucleotide repeat (TTTA)n in intron 5, about 80 nucleotides downstream of exon 4 has previously been described. The allele frequencies of the polymorphic repeat were studied in series of 182 sporadic and 185 familial breast cancer patients as well as in 252 healthy control individuals. Five different alleles containing 7, 8, 9, 11 and 12-TTTA-repeats were detected. A relatively rare allele (A1) containing the longest repeat (TTTA)12 was found significantly more frequently in breast cancer patients than in control individuals. This indicates that individuals carrying the A1 allele of CYP19 may have an increased risk of developing breast cancer, OR 2.42 (95% confidence interval [CI] 1.03-5.80). The higher frequency was observed in both sporadic and familial patients, although when each of the groups was compared to the control group only a borderline significance was seen. A higher frequency of A1 allele carriers was also found in the group of patients with positive estrogen receptor and progesterone receptor positive tumors. These data suggest that the CYP19 gene may be involved as a low penetrance gene in breast cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9511180     DOI: 10.1097/00008571-199802000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  23 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.

Authors:  Yan Guo; Dong-Hai Xiong; Tie-Lin Yang; Yan-Fang Guo; Robert R Recker; Hong-Wen Deng
Journal:  Hum Mol Genet       Date:  2006-06-16       Impact factor: 6.150

3.  A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.

Authors:  Janet E Olson; James N Ingle; Cynthia X Ma; Linda L Pelleymounter; Daniel J Schaid; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; Yanhong Wu; Fergus J Couch; Celine M Vachon; Thomas A Sellers; Richard M Weinshilboum
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

4.  Estrogen-related genes and their contribution to racial differences in breast cancer risk.

Authors:  Kerryn W Reding; Chu Chen; Kimberly Lowe; David R Doody; Christopher S Carlson; Christina T Chen; John Houck; Linda K Weiss; Polly A Marchbanks; Leslie Bernstein; Robert Spirtas; Jill A McDonald; Brian L Strom; Ronald T Burkman; Michael S Simon; Jonathan M Liff; Janet R Daling; Kathleen E Malone
Journal:  Cancer Causes Control       Date:  2012-03-15       Impact factor: 2.506

5.  Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.

Authors:  Barbara K Dunn; Mark H Greene; Jenny M Kelley; Joseph P Costantino; Robert J Clifford; Ying Hu; Gong Tang; Neely Kazerouni; Philip S Rosenberg; Daoud M Meerzaman; Kenneth H Buetow
Journal:  Int J Mol Epidemiol Genet       Date:  2010-09-05

6.  An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.

Authors:  Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson
Journal:  Fertil Steril       Date:  2009-12-11       Impact factor: 7.329

7.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

8.  CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Authors:  Ruth C Travis; Fredrick Schumacher; Joel N Hirschhorn; Peter Kraft; Naomi E Allen; Demetrius Albanes; Goran Berglund; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Eugenia E Calle; Stephen Chanock; Alison M Dunning; Richard Hayes; Heather Spencer Feigelson; J Michael Gaziano; Edward Giovannucci; Christopher A Haiman; Brian E Henderson; Rudolf Kaaks; Laurence N Kolonel; Jing Ma; Laudina Rodriguez; Elio Riboli; Meir Stampfer; Daniel O Stram; Michael J Thun; Anne Tjønneland; Dimitrios Trichopoulos; Paolo Vineis; Jarmo Virtamo; Loïc Le Marchand; David J Hunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-29       Impact factor: 4.254

9.  Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population.

Authors:  Khadijeh Onsory; R C Sobti; Adnan Issa Al-Badran; Masatoshi Watanabe; Taizo Shiraishi; Awtar Krishan; Harsh Mohan; Pushpinder Kaur
Journal:  Mol Cell Biochem       Date:  2008-05-16       Impact factor: 3.396

10.  Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.

Authors:  Qiuyin Cai; Nobuhiko Kataoka; Chun Li; Wanqing Wen; Jeffrey R Smith; Yu-Tang Gao; Xiao Ou Shu; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.